Long-term management of the liver transplant patient: Recommendations for the primary care doctor: Special feature

American Journal of Transplantation

Volumn 9, Issue 9, 2009, Pages 1988-2003

  McGuire, B M ^a   Rosenthal, P ^b   Brown, C C ^a   Busch, A M H ^c   Calcatera, S M ^a   Claria, R S ^d   Hunt, N K ^a   Korenblat, K M ^e   Mazariegos, G V ^f   Moonka, D ^g   Orloff, S L ^h   Perry, D K ⁱ   Rosen, C B ⁱ   Scott, D L ^h   Sudan, D L ^j  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ MAYO CLINIC   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

Immunosuppression; Liver; Long term; Management; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPSTEIN BARR VIRUS; GRAFT REJECTION; HEPATITIS C VIRUS; HUMAN; LIVER GRAFT; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; POLYMERASE CHAIN REACTION; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SEXUAL FUNCTION; THROMBOSIS;

ADULT; CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER DISEASES; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; PRIMARY HEALTH CARE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 69149107430     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02733.x     Document Type: Review

References (124)

1. McCashland TM. Posttransplantation care: Role of the primary care physician versus transplant center. Liver Transpl 2001 7 : S2 S12.
2. Abbasoglu O, Levy MF, Brkic F et al. Ten years after liver transplantation: An evolving understanding of late graft loss. Transplantation 1997 64 : 1801 1807.
3. Alloway RR, Isaacs R, Lake K et al. Report of the American Society of Transplantation conference of immunosuppressive drug and the use of generic immunosuppressants. Am J Transplant 2003 3 : 1211 1215.
4. Meier-Kriesche HU, Lib S, Gruessner RWG et al. Immunosuppression: Evolution in practice and trends 1994-2004. Am J Transplant 2006 6 : 1111 1131.
5. Pageaux GP, Rostaing L, Calmus Y et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006 12 : 1755 1760.
6. Belli LS, De Carlis L, Rondinara G et al. Early cyclosporine monotherapy in liver transplantation: A 5-year follow-up of a prospective, randomized trial. Hepatology 1998 27 : 1524 1529.
7. Bader FM, Hagan ME, Crompton JA, Gilbert EM. The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients. J Heart Lung Transplant 2005 24 : 2144 2147
8. Galioto A, Semplicini A, Zanus G et al. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: Results of a controlled clinical trial. Liver Transpl 2008 14 : 1020 1028
9. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000 22 : 441 457.
10. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998 34 : 429 455.
11. Levy G, Graxi GL, Sanjuan F et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 12 : 1464 1472.
12. Sampathkumar P, Paya CV. Management of cytomegalovirus infection after liver transplantation. Liver Transpl 2000 6 : 144 156.
13. Charlton M. Recurrence of hepatitis C infection: Where are we now? Liver Transpl 2005 11 (Suppl 2 S57 S62.
14. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 2005 80 (1 Suppl S120 S124.
15. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl 2006 12 : 1813 1824.
16. Lim JK, Keeffe EB. Liver transplantation for alcoholic liver disease: Current concepts and length of sobriety. Liver Transpl 2004 10 : S31 S38.
17. Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg 2007 205 : 108 123.
18. Almusa O, Federle MP. Abdominal imaging and intervention in liver transplantation. Liver Transpl 2006 12 : 184 193.
19. Moser M, Wall W. Management of biliary problems after liver transplantation. Liver Transpl 2001 7 : S46 S52.
20. Sawyer RG, Punch JD. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation 1998 66 : 1201 1207.
21. Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: Past, present and preventative strategies. Liver Transpl 2008 14 : 759 769.
22. Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl 2007 13 : 1645 1653.
23. Vallera RA, Cotton PB, Clavien PA. Biliary reconstruction for liver transplantation and management of biliary complications: Overview and survey of current practices in the United States. Liver Transpl Surg 1995 1 : 143 152.
24. Thethy S, Thomson BNJ, Pleass H et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 2004 18 : 647 653.
25. Johnston TD, Reddy KS, Khan TT, Ranjan D. ERCP in the management of early versus late biliary leaks after liver transplantation. Int Surg 2006 91 : 301 305.
26. Zhou G, Cai W, Li H, Zhu Y, Fung JJ. Experiences relating to management of biliary tract complications following liver transplantation in 96 cases. Chin Med J (Engl) 2002 115 : 1533 1537.
27. Branch MS, Claiven P. Biliary complications following liver transplantation. In : Claiven P, Killenberg PG, eds. Medical care of the liver transplant patient, 2nd Ed. Malden, MA : Blackwell, 2001 : 212 232.
28. Holt AP, Thorburn D, Mirza D, Gunson B, Wong T, Haydon G. A prospective study of standardized nonsurgical therapy in the management of biliary anastomotic strictures complicating liver transplantation. Transplantation 2007 84 : 857 863.
29. Pasha SF, Harrison ME, Das A et al. Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: Outcomes after maximal stent therapy. Gastrointest Endosc 2007 66 : 44 51.
30. Rerknimitr R, Sherman S, Fogel EL et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: Endoscopic findings and results of therapy. Gastrointest Endosc 2002 55 : 224 231.
31. Rizk RS, McVicar JP, Emond MJ et al. Endoscopic management of biliary strictures in liver transplant recipients: Effect on patient and graft survival. Gastrointest Endosc 1998 47 : 128 135.
32. Greif F, Bronsther OL, Van Thiel DH et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 1994 219 : 40 45.
33. KDOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002 39 (2 Suppl 1 S1 266.
34. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349 : 931 940.
35. Morard I, Mentha G, Spahr L et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006 20 : 96 101.
36. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003 9 : 741 747.
37. Wiesner RH, McDiarmid SV, Kamath PS et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl 2001 7 : 567 580.
38. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004 36 (2 Suppl 234S 239S.
39. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 2004 10 : 301 309.
40. Reuben A. Long-term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity. Liver Transpl 2001 7 (Suppl 1 S13 S21.
41. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000 70 (suppl S58 S63.
42. Durrbach A. Diabetes after transplantation. Nephrol Ther 2006 2 (Suppl 3 S197 S199.
43. Wahlstrom HE, Cooper J, Gores G, Rosen C, Wiesner R, Krom RAF. Survival after liver transplantation in diabetics. Transplant Proc 1991 23 : 1565 1566.
44. Steinmuller TH, Stockmann M, Bechstein WO, Settmacher U, Jonaas S, Neuhaus P. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000 108 : 401 405.
45. Navasa M, Bustamante J, Marroni C et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol 1996 25 : 64 71.
46. Bigam DL, Pennington JJ, Carpenteier A et al. Hepatitis C-related cirrhosis: A predictor of diabetes after transplantation. Hepatology 2000 32 : 87 90.
47. Marchetti P. New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl 2005 11 : 612 620. (Pubitemid 40872898)
48. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001 7 (Suppl 1 S22 S26.
49. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 1985 82 : 8222 8226.
50. Jain A, Reyes J, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term followup of the first 1000 patients. Ann Surg 1999 230 : 441 448.
51. Canzanello VJ, Textar SC, Taler SJ et al. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998 4 : 328 334.
52. Mells G. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007 83 : 1141 1150.
53. Avdonin PV, Cottet-Marie F, Afanasjeva GV et al. Cyclosporine A upregulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999 55 : 2407 2414.
54. Imagawa DK, Dawson S, Holt CD et al. Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxyl-methylglutaryl- coenzyme A reductase inhibitor pravastatin. Transplantation 1996 62 : 934 942.
55. Gisbert C, Prieto M, Berenguer M et al. Hyperlipidemia in liver transplant recipients: Prevalence and risk factors. Liver Transpl Surg 1997 3 : 416 422.
56. Charco R, Cantarell C, Vargas V et al. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 1999 5 : 204 208.
57. Munoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: Pathogenesis, diagnosis and management. Liver Transpl Surg 1995 1 (suppl 1 29 38.
58. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997 63 : 331 338.
59. Stegall MD, Everson GT, Schroter G et al. Prednisone withdrawal late after adult transplantation reduces diabetes, hypertension and hypercholesterolemia without causing graft loss. Hepatology 1997 25 : 173 177.
60. Everhart JE, Lombardero M, Lake JR et al. Weight change and obesity after liver transplantation. Incidence and risk factors. Liver Transpl Surg 1998 4 : 285 296.
61. Canzanello VJ, Schwartz L, Tater SJ, Textor SC, Wiesner RH, Porayko MK. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997 3 : 1 9.
62. Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001 7 : 363 273.
63. Cassiman D, Roelants M, Vandenplas G et al. Orlistat treatment is safe in overweight and obese liver transplant recipients: A prospective open label trial. Transpl Int 2006 19 : 1000 1015.
64. Tichansky DS, Madan AK. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. Obes Surg 2005 15 : 1481 1486.
65. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995 108 : 276 283.
66. Neuhaus R, Lohmann R, Platz KP et al. Treatment of osteoporosis after liver transplantation. Transplant Proc 1995 27 : 1226 1227.
67. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995 95 : 2581 2586.
68. Spolidorio LC, Nassar PO, Nassar CA, Spolidorio DM, Muscara MN. Conversiion of immunosuppressive monotherapy from ciclosporine a to tacrolimus reverses bone loss in rats. Calcif Tissue Int 2007 81 : 114 123.
69. Cunningham J. Posttransplantation bone disease. Transplantation 2005 79 : 629 634.
70. Zeldin GA, Maygers J, Klein A, Thuluvath PJ. Vaccination, screening for malignancy, and health maintenance of the liver transplant recipient. J Clin Gastroenterol 2001 32 : 148 150
71. Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine 2008 26 : 6859 6863.
72. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006 10 : 78 82.
73. Kano H, Mizuta K, Sakakihara Y et al. Efficacy and safety of immunization for pre-and post-liver transplant children. Clin Transplant 2002 74 : 543 550.
74. Scharpe J, Evenepoel P, Maes B et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008 8 : 332 337.
75. Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2007 138 : 739 745, 747 760
76. Thorp M, DeMattos A, Bennett W, Barry J, Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000 69 : 1218 1220.
77. Borg M, van der Wouden EJ, Sluiter WJ, Sloof M, Haagsma EB, Van Den Berg AP. Vascular events after liver transplantation: A long-term follow-up study. Transpl Int 2007 21 : 74 80.
78. Pungpapong S, Mazarbeitia C, Ortiz J et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl 2002 8 : 582 587.
79. Pastacaldi S, Teixeira R, Montalto P, Rolles K, Burroughs AK. Hepatic artery thrombosis after orthotopic liver transplantation: A review of nonsurgical causes. Liver Transpl 2001 7 : 75 81.
80. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M. Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008 134 : 432 439.
81. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors. Gastroenterology 2008 134 : 1699 1714.
82. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005 42 : 63 71.
83. Verweij PE, Kerremans JJ, Voss A, Meis JFGM. Fungal contamination of tobacco and marijuana. JAMA 2000 284 : 2875.
84. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006 154 : 498 504.
85. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004 30 (4 Pt 2 622 627.
86. Penn I. The incidence of malignancies in transplant recipients. Transplant Proc 1975 7 : 323 326.
87. Taylor AEM, Shuster S. Skin cancer after renal transplantation: The causal role of azathioprine. Acta Derm Venereol 1992 72 : 115 119.
88. Sanchez EQ, Marubashi S, Jung G et al. De-novo tumors after liver transplantation: A single-institution experience. Liver Transpl 2002 8 : 285 291.
89. Stasko T, Brown MD, Carucci JA et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004 : 30 (4 Pt 2 642 650. (Pubitemid 38525895)
90. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009 87 : 233 242.
91. Nalesnik MA, Starzl TZ. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transpl Sci 1994 4 : 61 79.
92. Newell KA, Alonso EM, Whitington PF et al. Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus and immunosuppression. Transplantation 1996 62 : 370 375.
93. Coher JI. Epstein-Barr virus infection. N Engl J Med 2000 343 : 481 492.
94. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005 26 : 631 645.
95. Tsai DE, Nearey M, Hardy CL, Tomaszewski J, Kotloff R. Use of EBV PCR for the diagnosis and monitoring of posttransplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002 2 : 946 954.
96. Armenti VT, Herrine SK, Radomski JS, Moritz MJ. Pregnancy after liver transplantation. Liver Transpl 2000 6 : 671 685.
97. Parolin MB, Rabinovitch I, Urbanetz AA, Scheidemantel C, Cat ML, Coelho JC. Impact of successful liver transplantation on reproductive function and sexuality in women with advanced liver disease. Transplant Proc. 2004 36 : 943 944.
98. Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 2003 102 : 121 128.
99. Coscia LA, Constantinescu S, Moritz MJ et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl 2007 29 42.
100. Cardonick E, Moritz M, Armenti V. Pregnancy in patients with organ transplantation: A review. Obstet Gynecol Surg 2004 59 : 214 222.
101. Birgerson LE. Important changes in the CellCept (mycophenolate mofetil) prescribing information - Use of CellCept is associated with increased pregnancy loss and congenital malformations/change from pregnancy category C to pregnancy category D. http://www.fda.gov/medwatch/safety/2007/cellcept-dearhcpoct07.pdf (accessed June 30, 2008).
102. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006 82 : 1698 1702.
103. Armenti VT, Radomski JS, Moritz MJ et al. Report from the national transplantation pregnancy registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transplant 2004 59 : 440.
104. Jain A, Venkataramanan R, Fung JJ et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997 64 : 559 565.
105. Armenti VT, Radomski JS, Moritz MJ et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl 2005 69 83.
106. Ho JK, Ko HH, Schaeffer DF et al. Sexual health after orthotopic liver transplantation. Liver Transpl 2006 12 : 1478 1484.
107. Madersbacher S, Grunberger T, Maier U. Andrological status before and after liver Transplantation. J Urol 1994 151 : 1251 1254.
108. Saab S, Wiese C, Ibrahim AB et al. Employment and quality of life in liver transplant recipients. Liver Transpl 2007 13 : 1330 1338.
109. Rongey C, Bambha K, Vanness D et al. Employment and health insurance in long-term liver transplant recipients. Am J Transplant 2005 5 : 1901 1908.
110. Blanch J, Sureda B, Flavia M et al. Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. Liver Transpl 2004 10 : 228 234.
111. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Health-related quality of life after liver transplantation: A meta-analysis. Liver Transpl Surg 1999 5 : 318 331.
112. Hunt CM, Tart JS, Dowdy E, Bute BP, Williams DM, Clavien PA. Effect of orthotopic liver transplantation on employment and health status. Liver Transpl Surg 1996 2 : 148 153.
113. Nickel R, Wunsch A, Egle UT et al. The relevance of anxiety, depression, and coping in patients after liver transplantation. Liver Transpl 2002 8 : 63 71. (Pubitemid 34092675)
114. Sahota A, Zaghla H, Adkins R et al. Predictors of employment after liver transplantation. Clin Transplant 2006 20 : 490 495.
115. Cowling T, Jennings LW, Goldstein RM et al. Societal reintegration after liver transplantation: Findings in alcohol-related and non-alcohol-related transplant recipients. Ann Surg 2004 239 : 93 98.
116. Horslen S, Barr ML, Christensen LL, Ettenger R, Magee JC. Pediatric transplantation in the United States, 1996-2005. Am J Transplant 2007 7 (5 Pt 2 1339 1358.
117. Bucuvalas JC, Ryckman FC. Long-term outcome after liver transplantation in children. Pediatr Transplant 2002 6 : 30 36.
118. Soltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R. Late graft loss or death in pediatric liver transplantation: An analysis of the SPLIT database. Am J Transplant 2007 7 : 2165 2171.
119. Kosmach B, Webber SA, Reyes J. Care of the pediatric solid organ transplant recipient. The primary care perspective. Pediatr Clin North Am 1998 45 : 1395 1418.
120. Martin SR, Atkison P, Anand R, Lindblad AS. Studies of pediatric liver transplantation 2002: Patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant 2004 8 : 273 283.
121. McDiarmid SV, Anand R. Studies of pediatric liver transplantation (SPLIT): A summary of the 2003 annual report. Clin Transpl 2003 : 119 130.
122. McDiarmid SV, Anand R, Lindblad AS. Studies of Pediatric Liver Transplantation: 2002 update. An overview of demographics, indications, timing, and immunosuppressive practices in pediatric liver transplantation in the United States and Canada. Pediatr Transplant 2004 8 : 284 294.
123. Jain A, Mazariegos G, Pokharna R et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: A long-term analysis. Transplantation 2003 75 : 1020 1025.
124. McDiarmid SV. Management of the pediatric liver transplant patient. Liver Transpl 2001 7 (11 Suppl 1 S77 S86.